Important Information for Investors of Sana Biotechnology, Inc.:
New York, April 9, 2025 – The Rosen Law Firm, a global investor rights law firm, alerts purchasers of Sana Biotechnology, Inc. (SANA) securities between March 17, 2023, and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for Sana Biotechnology investors under the Securities Act of 1933.
Background:
Sana Biotechnology is a clinical-stage biotechnology company focused on developing innovative therapies for genetically defined diseases. The company’s lead product candidate, SANA-101, is designed to reverse the genetic damage caused by sickle cell disease and beta-thalassemia. Sana Biotechnology’s mission is to transform the lives of patients with severe genetic diseases.
Allegations:
The complaint alleges that during the Class Period, Sana Biotechnology made materially false and misleading statements regarding the development and commercial potential of SANA-101. Specifically, the complaint alleges that the defendants failed to disclose that:
- SANA-101’s clinical trial data was insufficient to support its regulatory approval;
- SANA-101’s clinical trial data showed significant safety concerns;
- Sana Biotechnology had not obtained regulatory approval for SANA-101 in any jurisdiction;
- Sana Biotechnology’s partnership with Novartis AG was not as strong as represented;
Lead Plaintiff Deadline:
If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation as a class member or to opt out of the class, you must do so no later than May 20, 2025. A class action lawsuit is a lawsuit that represents the interests of all class members, who may choose to do nothing and be bound by the court’s decision, or to remain an active party in the litigation.
Impact on Individual Investors:
If you purchased Sana Biotechnology securities during the Class Period, you may be able to recover your losses as a class member. The Rosen Law Firm encourages you to contact them to discuss your potential recovery.
Impact on the World:
The outcome of this lawsuit could have significant implications for the biotech industry and investors. If the allegations are proven true, it could lead to increased scrutiny of biotech companies and their clinical trial data. It could also deter investors from investing in biotech companies without a clear regulatory pathway for their products. On the other hand, if the allegations are proven false, it could boost investor confidence in the biotech sector and lead to increased investment.
Conclusion:
The Rosen Law Firm encourages investors who purchased Sana Biotechnology securities during the Class Period to contact them before the May 20, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for investors under the Securities Act of 1933. The outcome of this lawsuit could have significant implications for the biotech industry and investors. Stay tuned for updates.
